Ayumu Niida

Ayumu Niida

Auto-generated profile, based on publicly available information

Ayumu Niida

Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2006 in Organic Letters
Verified
Journal Article
Closed access
ANAyumu Niida
Ayumu Niida
KTKenji Tomita
Kenji Tomita
MMMakiko Mizumoto
Makiko Mizumoto
HTHiroaki Tanigaki
Hiroaki Tanigaki
TTTomohiro Terada
Tomohiro Terada
NFNobutaka Fujii
Nobutaka Fujii

1 March 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KSKotaro Sakamoto
Kotaro Sakamoto
YKYusuke Kamada
Yusuke Kamada
TSTomoya Sameshima
Tomoya Sameshima
MYMasahiro Yaguchi
Masahiro Yaguchi
ANAyumu Niida
Ayumu Niida
ATAkiyoshi Tani
Akiyoshi Tani

1 February 2004 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TMToshihiko Masui
Toshihiko Masui
RDRyuichiro Doi
Ryuichiro Doi
TMTomohiko Mori
Tomohiko Mori
ETEiji Toyoda
Eiji Toyoda
MKMasayuki Koizumi
Masayuki Koizumi
MIMasayuki Imamura
Masayuki Imamura

15 May 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SSSatoshi Sogabe
Satoshi Sogabe
YKYusuke Kamada
Yusuke Kamada
MMMasanori Miwa
Masanori Miwa
ANAyumu Niida
Ayumu Niida
TSTomoya Sameshima
Tomoya Sameshima
KSKotaro Sakamoto
Kotaro Sakamoto

1 January 2006 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ANAyumu Niida
Ayumu Niida
ZWZixuan Wang
Zixuan Wang
KTKenji Tomita
Kenji Tomita
SOShinya Oishi
Shinya Oishi
HTHirokazu Tamamura
Hirokazu Tamamura
NFNobutaka Fujii
Nobutaka Fujii

1 July 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MTMasahiro Tsuda
Masahiro Tsuda
TTTomohiro Terada
Tomohiro Terada
MIMegumi Irie
Megumi Irie
TKToshiya Katsura
Toshiya Katsura
ANAyumu Niida
Ayumu Niida
KIKen-Ichi Inui
Ken-Ichi Inui
Midodrine is an oral drug for orthostatic hypotension. This drug is almost completely absorbed after oral administration and converted into its active form, 1-(2′,5′-dimethoxyphenyl)-2-aminoethanol) (DMAE), by the cleavage of a glycine residue. The intestinal H+-coupled peptide transporter 1 (PEPT1) transports various peptide-like drugs and has been used as a target molecule for improving the intestinal absorption of poorly absorbed drugs through amino acid modifications. Because midodrine meets these requirements, we examined whether midodrine can be a substrate for PEPT1. The uptake of midodrine, but not DMAE, was markedly increased in PEPT1-expressing oocytes compared with water-injected oocytes. Midodrine uptake by Caco-2 cells was saturable and was inhibited by various PEPT1 substrates. Midodrine absorption from the rat intestine was very rapid and was significantly inhibited by the high-affinity PEPT1 substrate cyclacillin, assessed by the alteration of the area under the blood concentration-time curve for 30 min and the maximal concentration. Some amino acid derivatives of DMAE were transported by PEPT1, and their transport was dependent on the amino acids modified. In contrast to neutral substrates, cationic midodrine was taken up extensively at alkaline pH, and this pH profile was reproduced by a 14-state model of PEPT1, which we recently reported. These findings indicate that PEPT1 can transport midodrine and contributes to the high bioavailability of this drug and that Gly modification of DMAE is desirable for a prodrug of DMAE.